323105 VU Innovation & Leadership in Preclinical Drug Development - MPS5 (2024S)
Prüfungsimmanente Lehrveranstaltung
Labels
An/Abmeldung
Hinweis: Ihr Anmeldezeitpunkt innerhalb der Frist hat keine Auswirkungen auf die Platzvergabe (kein "first come, first served").
- Anmeldung von Fr 09.02.2024 19:39 bis Mo 01.04.2024 12:00
- Abmeldung bis Mo 01.04.2024 12:00
Details
Sprache: Englisch
Lehrende
Termine (iCal) - nächster Termin ist mit N markiert
Montag
04.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Dienstag
05.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Mittwoch
06.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Montag
11.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Mittwoch
13.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Montag
18.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Dienstag
19.03.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Dienstag
09.04.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Donnerstag
11.04.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Mittwoch
17.04.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Donnerstag
18.04.
16:45 - 18:45
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Dienstag
23.04.
16:45 - 19:15
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Donnerstag
25.04.
17:00 - 20:00
Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Information
Ziele, Inhalte und Methode der Lehrveranstaltung
Art der Leistungskontrolle und erlaubte Hilfsmittel
1. Attendance & Participation: participants are expected to attend all course sessions and actively participate in the course.
2. Three team oral presentations and exercises to be handed in as outlined during the course.
3. Participants will be assessed individually on attendance, application of concepts learned in class, relevant participation in discussions, active and meaningful contribution to team assignments and exercises.
2. Three team oral presentations and exercises to be handed in as outlined during the course.
3. Participants will be assessed individually on attendance, application of concepts learned in class, relevant participation in discussions, active and meaningful contribution to team assignments and exercises.
Mindestanforderungen und Beurteilungsmaßstab
-Class attendance.
- Active participation in class and with team.
- Deliver assignments as outlined in class.
- Three (3) oral presentations (team effort).
Final Presentation (3rd)- Final evaluation. Presentation of pitch and early stage solution design concept (team effort).
- Active participation in class and with team.
- Deliver assignments as outlined in class.
- Three (3) oral presentations (team effort).
Final Presentation (3rd)- Final evaluation. Presentation of pitch and early stage solution design concept (team effort).
Prüfungsstoff
Required Final Assignment - Oral presentation with a developed story line (Pitch), and a primitive prototype design (early stage mock-up of the design concept) [team effort]. Presentation to be submitted by email (PPT, KEY or OpenOffice formats) before it is given orally. Content and requirements to be discussed in class.
Literatur
Recommended Reading (optional):
1. Ross, Alec. The Industries of the Future. Simon & Schuster, 2016.
2. Kelley, Tom. The Art of Innovation. New York: Doubleday, 2005.
3. Gallo, Carmine. The Innovation Secrets of Steve Jobs. New York: McGraw-Hill, 2011, 31.
4. Vise, David & Mark Malseed. The Google Story. New York: Dela- corte Press, 2005, 256.
5. John Battelle. The Search: How Google and Its Rivals Rewrote the Rules of Business and Transformed Our Culture. New York: Penguin Group, 2005, 141.
6. Dyer, Jeff, Hal Gregersen & Clayton M. Christiansen. The Innovator’s DNA. Boston, MA: Harvard Business School Press, 2011.
7. Christensen, Clayton M. & Michael Raynor. Innovator’s Solution. Boston, MA: Harvard Business School Press, 2003.
8. Christensen, Clayton M. The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail. Boston, MA, Harvard Business School Press, 1997.
9. Christensen, Clayton M. Meeting the Challenge of Disruptive Change. Harvard Bus. School Press, 1997.
10. “The Life and Work of Dr. Paul." https://www.janssen.com/belgium/life-and-work-dr-paul
11. Abou-Gharbia, M. & Childers, W.E. Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 1. Criticisms Faced by the Pharmaceutical Industry. J. Med. Chem. (2016):56, 5659.
12. Brown, Tim. Design Thinking. Harvard Business Review (2008), 84.
13.Elvidge, S. Footfalls & Heartbeats: Smart knitted textiles for quanti ed self and patient monitoring Start-Up, 17 December 2013. https://www.innovationintextiles.com/footfalls-heartbeats-launches-crowdfunding-campaign-to-produce-smart-knitted-fabrics/
14. Szcerba, R.J. No Donor Required: 5 Body Parts You Can Make With 3-D Printers. Forbes, 17June 2016. https://www.forbes.com/sites/robertszczerba/2015/06/17/no-donor-required-5-body-parts-you-can-make-with-3-d-printers-2/#
15. Szczerba, R.J. Why Mobile Health Technologies Haven’t Taken Off (Yet). Forbes, 16 July 2014. https://www.forbes.com/sites/robertszczerba/2014/07/16/why-mobile-health-technologies-havent-taken-off-yet/#2bfcf73076ed
1. Ross, Alec. The Industries of the Future. Simon & Schuster, 2016.
2. Kelley, Tom. The Art of Innovation. New York: Doubleday, 2005.
3. Gallo, Carmine. The Innovation Secrets of Steve Jobs. New York: McGraw-Hill, 2011, 31.
4. Vise, David & Mark Malseed. The Google Story. New York: Dela- corte Press, 2005, 256.
5. John Battelle. The Search: How Google and Its Rivals Rewrote the Rules of Business and Transformed Our Culture. New York: Penguin Group, 2005, 141.
6. Dyer, Jeff, Hal Gregersen & Clayton M. Christiansen. The Innovator’s DNA. Boston, MA: Harvard Business School Press, 2011.
7. Christensen, Clayton M. & Michael Raynor. Innovator’s Solution. Boston, MA: Harvard Business School Press, 2003.
8. Christensen, Clayton M. The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail. Boston, MA, Harvard Business School Press, 1997.
9. Christensen, Clayton M. Meeting the Challenge of Disruptive Change. Harvard Bus. School Press, 1997.
10. “The Life and Work of Dr. Paul." https://www.janssen.com/belgium/life-and-work-dr-paul
11. Abou-Gharbia, M. & Childers, W.E. Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 1. Criticisms Faced by the Pharmaceutical Industry. J. Med. Chem. (2016):56, 5659.
12. Brown, Tim. Design Thinking. Harvard Business Review (2008), 84.
13.Elvidge, S. Footfalls & Heartbeats: Smart knitted textiles for quanti ed self and patient monitoring Start-Up, 17 December 2013. https://www.innovationintextiles.com/footfalls-heartbeats-launches-crowdfunding-campaign-to-produce-smart-knitted-fabrics/
14. Szcerba, R.J. No Donor Required: 5 Body Parts You Can Make With 3-D Printers. Forbes, 17June 2016. https://www.forbes.com/sites/robertszczerba/2015/06/17/no-donor-required-5-body-parts-you-can-make-with-3-d-printers-2/#
15. Szczerba, R.J. Why Mobile Health Technologies Haven’t Taken Off (Yet). Forbes, 16 July 2014. https://www.forbes.com/sites/robertszczerba/2014/07/16/why-mobile-health-technologies-havent-taken-off-yet/#2bfcf73076ed
Zuordnung im Vorlesungsverzeichnis
Letzte Änderung: Do 08.02.2024 19:46
This course is in English and fulfills 2 ECTS.
An experiential learning method allows students to apply concepts covered in class to real situations.
- Laptops, tablets, phones or other devices are allowed and encouraged in this class. These tools will enable you to search the internet and gather information for your projects and class discussion.